Eat & Beyond

Eat & Beyond focuses on early-stage and growth-stage companies in the alternative-protein sector. It invests in startups developing plant-based, fermentation-derived, and cell-cultured food products. The firm typically leads or co-leads equity rounds in private companies.

No. The firm's mandate is explicitly focused on alternative proteins—plant-based, fermentation-derived, and cell-cultured foods. It does not invest in conventional livestock or traditional agriculture businesses. This narrow sector focus is a distinguishing characteristic.

The firm primarily invests in companies based in North America. It has selectively considered international opportunities in the alternative-protein space, but North America is the core market for its deployed capital.

Eat & Beyond sources deals through its network in the food-tech and venture-capital ecosystem, including co-investor relationships, industry conferences, and direct outreach to startups. The firm's specialist focus on alternative proteins allows it to build proprietary relationships in the sector.

Eat & Beyond is structured as an asset manager, raising discrete pools of capital from institutional and accredited investors. It operates as a private equity firm with a specialized sector mandate, not as a permanent-capital family office.

The firm invests across multiple technology approaches, including plant-based meat and dairy substitutes, precision fermentation for ingredients, and cell-cultured meat development. It also supports manufacturing and supply-chain innovations that enable these categories.

Publicly available records do not detail specific portfolio company names. The firm describes its investments as covering early-stage private companies in the alternative-protein value chain, but a full list of holdings is not publicly disclosed as of this writing.